Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of DA-2802 in Chronic Hepatitis B Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with chronic hepatitis B aged 18 years or older~* Subjects who have evidence to demonstrate a history of chronic hepatitis B for at least six months from the time of screening visit~* Subjects who have HBsAg positive test at screening visit~* Subjects who did not receive the hepatitis B treatment, including interferon or pegylated interferon, within 24 weeks of starting the screening test~* Subjects with an ALT of 80 units or more and 10 times lower than the normal upper limit at the time of screening~Exclusion Criteria:~* Subjects infected with hepatitis C, hepatitis D or human immunodeficiency virus~* Subjects with creatinine clearance of less than 50 ml/min at the screening visit~* At the time of screening visit, alpha-fetoprotein level was higher than 50 ng/ml and related imaging test showed hepatocellular carcinoma~* Subjects with decompensated liver disease who meet the following criteria:~  1. Total bilirubin levels greater than 2.5 mg/dl~ 2. Prothrombin time is at least 3 seconds longer than normal upper limit~ 3. Serum albumin value less than 30 g/l~ 4. Subjects with a history of ascites, jaundice, bleeding from varicose veins, hepatic encephalopathy, or other signs of liver failure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DA-2802 (Type: EXPERIMENTAL): DA-2802 319mg tablet qd
- Viread® (Type: ACTIVE_COMPARATOR): Viread® 300mg tablet qd

Based on this trial design, predict the completion outcome and termination type (if applicable).